FAQ

A1: Eligible research projects are those that have direct relevance to T1D and explore translational immunology. This includes, but is not limited to, novel pathways of autoimmunity in T1D, new approaches to early detection of at-risk individuals, biomarker strategies (especially for prediction of T1D disease progression and stratification for clinical response to immunotherapy), and applications of artificial intelligence and/or machine learning in any of these research topics. See Requirements page for further details on eligibility.

A2: Research grants are not eligible for:

• Research connected to any Sanofi product
• Studies for which extensive data is already published
• Comparative drug trials, randomized clinical trials, or placebo-controlled trials or studies requiring a drug supply
• Research projects for which the risk/benefit of any interventional treatment is considered uncertain, based on the scientific rationale, mechanism of action, and potential safety concerns
• Research projects that are already included in Investigator-Sponsored Studies by Sanofi and/or listed on www.clinicaltrials.gov. See Requirements page for further details on eligibility.

A3: Not-for-profit organizations, such as universities and research institutes, are eligible to apply. The application should be signed by the Principal Investigator and a Legal Representative (i.e., a representative from the legal department of the applicant’s research institution). The Principal Investigator is the person responsible for the conduct of the research project and has permission from their Institution to apply for a grant. Grants are provided to appropriate institutions and are never awarded nor paid out to individuals. 
See Requirements for further details on eligibility.

A4: Research projects that have already received funding from a separate grant program are eligible for funding via the T1D Innovation Grant Program.  However, duplicate funding is not allowed. In other words, you may not apply for funding for budget items already covered by a different grant. In the Legal Terms and Conditions section, please see the information about Medical Contributions Application - Principles and Conditions and Medical Contributions Application - Approval Requirements.

A5: No, but once you have received the decision on your application, you will be able to apply with a different proposal in a subsequent application window. Further information on the application process can be found here.

A6: If the applicant is different from the PI, it is the PI's CV that needs to be uploaded during the application submission process. Please ensure you have this document ready when submitting your application.

A7: While a project may involve multiple investigators, only one should be designated as the main PI during the application submission process. This helps streamline communication and responsibility allocation throughout the grant period.

A1: The selection process involves an initial quality check by an internal review panel, followed by an in-depth evaluation by an external scientific expert panel. The five highest-ranked projects will then proceed to Sanofi's Medical Contribution Process for final legal and compliance validation.

A2: After communication of success in the process, institutions will be required to sign a contract and apply for ethical / IRB +/- required regulatory approvals.

A3: Successful candidates whose proposal is selected for funding support and who successfully complete an internal due diligence check, by Sanofi on the iENVISION platform, will be expected to sign a contract which memorializes the terms and conditions specified at the beginning of the grant application process. Grant recipients will be asked to provide progress reports and a final report to track the advancement of their research. Publication in a peer-reviewed journal is highly encouraged to share your valuable findings with the scientific community. The investigators may be invited to speak at Sanofi events. Successful applicants will be invited to record a virtual presentation to be shown at the grant award ceremony at the 21st Immunology of Diabetes Society (IDS) Congress (April 2026, Brisbane, Australia).

A4: Applications submitted during the November 24 to December 19 2025 window will undergo the review process following the closing of the application period. More information available here.

A5: Once your application has entered the review process, it cannot be edited or withdrawn. However, in special circumstances, you may contact us for assistance at info@t1dinnovgrant.com.

A1: Researchers can apply for a grant of up to €140,000 for each research project. The total available funding across all successful research grants is €700,000.

A2: For detailed information on what to include in the Budget and Materials sections, please refer to the Budget and Materials Checklist provided in the Application Guide. This checklist provides you with a comprehensive list of all necessary items and information needed for these sections of your application.

A3: The overhead policy refers to the guidelines on how additional expenses beyond the direct costs of research, such as administrative costs and facilities maintenance, are handled. This document should be in PDF format, on the institution's letterhead, and signed by a legal representative of the research center. It must be provided in English. If the original document is in another language, the applicant should provide a translation of the sections related to the overhead policy. The overhead percentage stated in this document should match the percentage reported in the Budget File.

A4: A CPT (Current Procedural Terminology) code, developed by the American Medical Association (AMA), provides a standard language and numerical coding system to accurately communicate medical, surgical, diagnostic, and therapeutic services across various stakeholders, including patients. This system is applicable in the US. For ex-US applicants, providing a CPT code is optional when filling in the budget tracker.

A1: The applicable retention period is 3 years for your registration in our database and 5 years for the processing of your personal data. Collected personal data will be removed at the end of the retention period.

A2: You have the option to delete your account and all associated personal data in the reserved area of your account settings. User accounts will be deactivated and all associated data deleted after 30 months. See the Privacy policy for further information on data retention.

A3: Your application will remain securely saved in your profile. Once the website resumes accepting applications, you will be able to submit it.

A4: We appreciate your understanding that all applications must be submitted through our online platform for consistency and fairness. Unfortunately, we cannot accept revised applications via email. However, you will have the opportunity to resubmit your revised application on the platform in the next grant application opening. Please note that the application opening on 24 November 2025 is the first for the T1D Innovation Grant Program and this program will be maintained in future years.

A5: If you have further questions, please contact us by email at info@t1dinnovgrant.com. 
You can also find our contact form on the Contact Us page.